Request Demo

Last update 07 Jul 2026

Tamoxifen Citrate

Last update 07 Jul 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine, 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene

+ [20]

Target

Action

antagonists

Mechanism

ERs antagonists(Estrogen receptors antagonists)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication

Estrogen receptor positive breast cancerNoninfiltrating Intraductal CarcinomaBreast Cancer

Inactive Indication

Advanced Malignant Solid NeoplasmBreast Cancer, FamilialDementia+ [10]

Originator Organization

AstraZeneca PLC

Active Organization

Mayne Pharma Commercial LLC

Suzhou First Pharmaceutical Co., Ltd.AstraZeneca KK

Inactive Organization

AstraZeneca PLCAstraZeneca Pharmaceuticals LP

Daré Bioscience, Inc.

License Organization

Midatech Pharma US, Inc.

DARA BioSciences, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (30 Dec 1977),

Breast Cancer

RegulationOrphan Drug (European Union)

Structure/Sequence

Molecular FormulaC32H37NO8

InChIKeyFQZYTYWMLGAPFJ-OQKDUQJOSA-N

CAS Registry54965-24-1

440

Clinical Trials associated with Tamoxifen Citrate

NCT07535905

/ Not yet recruitingPhase 2IIT

Phase II Controlled Clinical Trial to Test Efficacy and Observe Longitudinal Effects of Tamoxifen for Testosterone Recovery in Medically Castrated Prostate Cancer Patients

Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in 10-25% of cases. The hypogonadal state has significant psychosocial and physical side effects. Therefore, limiting ADT effect's duration beyond the prescribed castration period is very compelling to patients and providers alike.
Tamoxifen, a well-established selective estrogen receptor modulator, offers a novel and cost-effective approach to accelerate testosterone recovery in men with secondary hypogonadism. This project addresses a critical gap in global cancer care by evaluating Tamoxifen as a viable solution for reducing the burden of delayed testosterone recovery and its associated side effects, particularly in resource-limited settings.

Start Date01 Jul 2026

Sponsor / Collaborator

University Health Network

JPRN-jRCTs031260249

/ Not yet recruitingPhase 2

A randomized study of Trastuzumab deruxtecan Against Second-line endocrine Therapy In hormone receptor-positive, HER2-low/ultralow metastatic breast cancer (TRANSITION)

Start Date29 Jun 2026

Sponsor / Collaborator-

TCTR20260411005

/ Not yet recruitingPhase 4IIT

Efficacy of Short-Course Tamoxifen versus Combined Oral Contraceptive Pills in Managing Unscheduled Bleeding among Levonorgestrel Implant (Jadelle) Users

Start Date23 Mar 2026

Sponsor / Collaborator-

100 Clinical Results associated with Tamoxifen Citrate

100 Translational Medicine associated with Tamoxifen Citrate

100 Patents (Medical) associated with Tamoxifen Citrate

12,032

Literatures (Medical) associated with Tamoxifen Citrate

01 Apr 2026·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Human serum albumin-based polymeric nanoparticles for ratiometric co-encapsulation and co-delivery of palbociclib and tamoxifen citrate for synergistic effect in breast cancer management

Article

Author: Sharma, Anamika ; Yadav, Pooja ; Chourasia, Manish K ; Sonone, Prajyot R ; Gupta, Ujala ; Bharath, M ; Bhandari, Vasundhra ; Singh, Pankaj Kumar ; Mungalasetty, Sharon

In conventional co-delivered chemotherapeutic strategies, the disparity in physicochemical properties and non-coordinated pharmacokinetic profile is largely overlooked. To overcome these long-standing challenges, we prepared a Palbociclib (PAL) and Tamoxifen citrate (TC) co-loaded in a synergetic fashion into a Human serum albumin nanoparticle (PAL/TC-HSA-NPs). It was optimised through Box-Behnken design of experiment and had a Particle size, Polydispersity index, and zeta potential of 155.7 ± 8.12 nm, 0.15 ± 0.01, and - 19.52 ± 2.04 mV. At both pH conditions of 5.5 and 7.4, it displayed a prolonged release profile over 48 h. The molecular dynamics and simulation study confirmed an energetically stable protein-ligand interaction and well-submerged active moieties in the binding pockets of HSA. The maximal in vitro cytotoxicity caused by PAL/TC-HSA-NPs is attributed to a synergistic effect, along with active targeting achieved via the gp60 and SPARC proteins. In a flow cytometry study, PAL/TC-HSA-NPs showed maximal apoptosis and G0/G1 phase arrest in MDA-MB-231 cells. The AUC_0-t for PAL and TC in PAL/TC-HSA-NPs were found to be 26.16 ± 4.2 ppm*h and 18.25 ± 2.5 ppm*h, respectively, which were 1.17-fold and 1.44-fold higher than PAL and TC in PAL-TC (1:1) solution. The final tumour weight was found to be 2.62-fold reduced in comparison to the free PAL-TC group. In in vivo bioimaging, after a 24 h study, FITC-HSA-NP showed a pronounced fluorescence signal at the tumour site that remained detectable over an extended period. Overall, PAL/TC-HSA-NPs showed excellent tumour targeting, efficacy and biosafety.

01 Apr 2026·NEUROMUSCULAR DISORDERS

Safety and Efficacy of Tamoxifen in Patients with Duchenne muscular dystrophy: open Label Extension of TAMDMD Trial

Article

Author: Spinty, Stefan ; Zwingli, Gaëtan ; Lawrence, Fiona ; Lopez Lobato, Mercedes ; Houwen-van Opstal, Saskia ; Schara-Schmidt, Ulrike ; Laugel, Vincent ; Amthor, Helge ; Schaedelin, Sabine ; Nascimento Osorio, Andrés ; Rubino-Nacht, Daniela ; Hafner, Patricia ; Deconinck, Nicolas ; Putananickal, Niveditha ; Fischer, Dirk ; Horrocks, Iain ; von Moers, Arpad ; Childs, Anne-Marie ; Henzi, Bettina C ; Dorchies, Olivier M ; Nagy, Sara ; Schmidt, Simone

Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy was assessed in the double-blind, randomised, placebo-controlled, multicenter phase 3 trial (TAMDMD), which was followed by an 48 weeks open label extension study. The aim of the open label extension study was to investigate if earlier initiation of tamoxifen could reduce the progression of the disease compared to delayed initiation of tamoxifen. Of the initial TAMDMD trial participants, 66 patients were enrolled in the open label extension (OLE). The objective was to investigate the efficacy of prolonged treatment with tamoxifen 20 mg daily, adjunct to corticosteroids, in individuals with DMD over 48 weeks. We aimed to analyse the sustained effect and the timing effect of tamoxifen in patients with DMD on the basis of a set of motor function tests. The sustained effect corresponds to the treatment effect seen in the tamoxifen treatment arm of the RCT phase of the trial being sustained after all patients got the treatment in the OLE phase. The timing effect addresses if patients with earlier tamoxifen initiation show more favourable disease trajectory than patients with delayed tamoxifen initiation. This study was registered with ClinicalTrials.gov (NCT03354039). Between May 28th 2019 and July 28th 2021, 66 patients in 10 study centres in seven European countries could be enrolled into the OLE phase. Of those, 32 had previously been treated with tamoxifen and 34 had been assigned to placebo. The efficacy outcome defined as the change in the motor function did not differ significantly between the early tamoxifen treatment group and the delayed tamoxifen treatment group. There was neither a sustained nor a timing effect of tamoxifen. Overall tamoxifen was well tolerated. No deaths or life-threatening serious adverse events occurred. The OLE phase of the TAMDMD trial showed that treatment with tamoxifen continued to be well tolerated overall; however, there was neither a sustained nor a timing effect of tamoxifen treatment in patients with DMD. We cannot provide statistical nor clinical evidence that prolonged treatment with tamoxifen is effective in delaying disease progression in DMD when used as an adjunct to corticosteroids.

24 Mar 2026·JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Deciphering the in silico molecular mechanism of coumestrol activity for uterine fibroids remedy: a promising estrogenic target drug candidate

Article

Author: Chtita, Samir ; Munir, Aqsa ; Olowosoke, Christopher Busayo ; Ojo, Oluwafemi Adeleke ; Khedraoui, Meriem ; Sofela, Salimat Opeyemi ; Ibisanmi, Tope Abraham ; Taiwo, Odunayo ; Eze, Chioma Joy ; Osuagwu, Olachi Lilian ; Babatope, Valerie Onyia

Uterine fibroids (UF) are reproductive conditions that occur as tumours in the womb. It is a gynecological outgrowth of diverse sizes often allied with infertility risks that might require surgery to reduce the complication in the worst-case scenario in women. Recent studies have uncovered that estrogen can induce and facilitate other target pathways' action on target cells for UF's pathogenesis, among the targets probed for pharmaceutical intervention. This study screens the interaction effects of 32 phytochemicals from indigenous and adopted potent Chinese plants and herbs; Chamomile, Pomegranate, Red clover, Cinnamomum, and Date palm, against estrogen receptor alpha (ESRα) to serve for anti-UF drug candidates using in silico tools through the molecular mechanisms. The interaction identifies coumestrol as the best-docked candidate (-9.6 kcal/mol) with a correlation to the binding free energy (-30.487 kcal/mol) as compared to the standard drug tamoxifen (-9.3 kcal/mol; -46.928 kcal/mol). The downstream post-docking evaluation reveals coumestrol to have excellent pharmacokinetics, drug-likeness, leadlikeness (no violation), less toxic (LD50; 2991 mg/kg), and highly interactive with ESRα. Coumestrol was top-ranked for ESRα (1QKU) target by PharmMapper among 300 human protein targets, with a z-score of 1.19368. The density functional theory (DFT) and dynamic simulation of 200 ns reveal regions of coumestrol structure and its complex that contribute to the chemical reactivity, stability, flexibility, and compactness of druggability. Ultimately, coumestrol emerged as a potential candidate suitable for anti-UF management, therefore future direction for its application should be on the design and synthesis of new structural derivatives for further in silico, in vitro, and in vivo studies.

130

News (Medical) associated with Tamoxifen Citrate

06 Jun 2026

·www.sciencedaily.com

A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings are promising but not yet proof, and clinical trials are now being planned to test whether these drugs could help prevent breast cancer.Popular medications such as Ozempic, Wegovy, Mounjaro, and Zepbound may offer an unexpected benefit beyond helping people lose weight and manage diabetes. New research involving more than 110,000 women found that those taking GLP-1 drugs, a category that includes semaglutide-based medications like Ozempic and Wegovy, were significantly less likely to develop breast cancer. The findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and published in JCO Oncology Practice. Researchers reported that women using GLP-1 medications had roughly a 30% lower likelihood of developing breast cancer compared with women who were not taking the drugs. "While our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, it does add to the growing body of evidence suggesting that it's worth investigating these weight-loss drugs as potential cancer prevention tools," said Elizabeth McDonald, MD, PhD, a professor of Radiology at the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn's Abramson Cancer Center. Ozempic, Wegovy, and Other GLP-1 Drugs Draw Cancer Research Interest GLP-1 medications mimic a naturally occurring hormone called glucagon-like peptide-1, which helps regulate appetite and blood sugar levels. The class includes semaglutide drugs such as Ozempic and Wegovy, as well as tirzepatide medications including Mounjaro and Zepbound. Although originally developed to treat type 2 diabetes, these drugs have become some of the most widely used weight-loss medications in the United States. In recent years, several observational studies have suggested that GLP-1 drugs may be associated with lower risks for certain cancers or improved outcomes among cancer survivors. However, researchers stress that observational studies alone cannot prove cause and effect. Large prospective clinical trials are still needed to determine whether the medications directly reduce cancer risk. To answer that question, McDonald and her colleagues are working to launch a multisite clinical trial examining whether GLP-1 medications can lower breast cancer incidence in women considered high risk, including some with a previous history of breast cancer. "GLP-1 medications are intriguing from a cancer research perspective because they weren't designed for cancer therapy, but they do affect many different targets and pathways associated with cancer development, so we're eager to study them in this context," McDonald said. Study of More Than 110,000 Women Finds Lower Breast Cancer Rates The research team reviewed electronic health records from 111,646 women between the ages of 45 and 80 who had a body mass index (BMI) of 25 or higher and underwent breast imaging within the Penn Medicine health system between January 2022 and June 2025. Among those women, 15,264 (13.7 percent) had documented prescriptions for GLP-1 medications, while 96,382 (86.3 percent) had no documented exposure to the drugs. Researchers evaluated new breast cancer diagnoses in two separate groups. The first included the entire population of 111,646 women. The second was a matched cohort of 30,528 women, pairing each GLP-1 user with a nonuser who shared similar characteristics, including age, race, ethnicity, BMI, breast density, and diabetes status. This approach was designed to reduce bias and account for potential confounding factors. The results were consistent in both analyses. In the full study population, women taking GLP-1 medications had 35.1 percent lower odds of developing breast cancer. In the matched analysis, they had 30.5 percent lower odds. The researchers noted several limitations. The study did not distinguish between specific medications such as Ozempic, Wegovy, Mounjaro, or Zepbound. It also did not account for treatment duration, genetic risk factors, cancer stage, or tumor subtype. Additional analyses are planned to examine some of these variables. Why Weight-Loss Drugs Might Influence Breast Cancer Risk Scientists have long recognized that maintaining a healthy weight is an important part of breast cancer prevention. Excess weight, particularly after menopause, is a well-established risk factor for the disease. Because GLP-1 medications are highly effective at promoting weight loss, some of the observed benefit may be related to weight reduction. However, researchers suspect other biological mechanisms could also be involved. Chronic low-grade inflammation has long been considered a possible contributor to breast cancer development. GLP-1 drugs are known to reduce inflammation through several pathways. They also influence metabolism and can affect epigenetic processes that help regulate gene activity. Researchers currently believe these combined effects may help suppress the development of breast cancer. Could Ozempic and Similar Drugs Help Prevent Breast Cancer? Current options for reducing breast cancer risk remain relatively limited. Along with routine screening through mammography or MRI, some individuals with inherited genetic mutations that greatly increase breast cancer risk may choose preventive surgery, including prophylactic mastectomy. Tamoxifen can substantially reduce breast cancer incidence in high-risk patients, but many eligible women do not take the drug because of concerns about side effects. By contrast, GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are already being used by millions of Americans, making them an especially appealing area for future prevention research. "Ultimately, we want to find better options to prevent breast cancer," McDonald said. "It's been encouraging to see the survival rates for breast cancer improve over recent decades, and we'd love to see the same gains in prevention." The study was supported by the American College of Radiology Center for Research and Innovation, the Pennsylvania Breast Cancer Coalition, and the Abramson Cancer Center.

04 Jun 2026

·www.fredhutch.org

Dr. Nancy Davidson receives national cancer award

Nancy E. Davidson, MD, executive vice president and chief academic officer at Fred Hutch Cancer Center, is the recipient of the David Karnofsky Science of Oncology Award from the American Society for Clinical Oncology (ASCO). Davidson, a medical oncologist and holder of the Raisbeck Endowed Chair for Collaborative Research, was honored during the 2026 ASCO annual meeting last Saturday in Chicago. In her introduction to Davidson’s 2026 David Karnofsky Science of Oncology Award Lecture, Lynn Schuchter, MD, FASCO, an ASCO past president and chair of the Joint Special Awards Selection Committee, described Davidson’s decades of work unraveling the mysteries of hormone-positive breast cancer in premenopausal women. “This award recognizes the pioneers of our field, those whose life work has fundamentally shifted how we understand and treat cancer,” Schuchter said. “[Davidson] has shaped the modern treatment strategies for breast cancer patients around the world.” Davidson's leadership in designing and leading clinical trials has led to major strides in the treatment of estrogen receptor (ER) positive breast cancer in premenopausal women. Among her discoveries was establishing the effectiveness of ovarian function suppression and tamoxifen, a selective estrogen receptor modulator (SERM) that works by blocking estrogen from binding to its receptors on cancer cells, in addition to chemotherapy for this population. Davidson shared these and other critical research findings on hormone-positive breast cancer treatment in her lecture, titled “Lessons from the Puzzle of Endocrine Therapy for Early-Stage Hormone-Responsive Breast Cancer in Premenopausal Women,” which she delivered from the main stage at ASCO. “Estrogen or progesterone receptor positive breast cancer accounts for about two-thirds of premenopausal breast cancer, and it remains a substantial challenge,” Davidson told the audience of cancer researchers, clinicians, patient advocates and other oncology professionals. She described how, as a young faculty member at Johns Hopkins University, she initially questioned the then-accepted belief that hormone therapy (also referred to as endocrine therapy) for hormone-positive breast cancer was not useful. Funded in part by a 1986 ASCO Young Investigator Award, Davidson modeled estrogen deprivation in a model organism, demonstrating that estrogen withdrawal led to a rapid decline in cancer cell growth and an increase in cell death among existing cancer cells in a hormone-positive breast cancer tumor. The work led to clinical trials demonstrating that treatments targeting estrogen receptor activity in pre-menopausal women with hormone positive breast cancer could indeed have a significant positive effect. Subscribe to Fred Hutch News You will receive a monthly newsletter from us about our innovative research and compassionate care as well as updates on events and other helpful tools and tips. You may unsubscribe at any time. In particular, the innovation of adding tamoxifen and ovarian function suppression to treatment plans for premenopausal women represented a major change from the “all-chemotherapy, all the time” previous standard of care, Davidson said. “And I think we established an unequivocal role for mechanism-based targeted endocrine therapies in these young women.” In her lecture, Davidson described how decades of basic science research have led to groundbreaking changes in how cancer is treated. “Better understanding of tumor biology led to the advent of novel therapeutics like targeted therapies, antibody drug conjugates, and immunotherapy that could potentially be combined with endocrine therapy,” she said. “Understanding endocrine resistance has allowed us to adopt agents like CDK4/6 inhibitors across the early and metastatic breast cancer continuum. Translational research enabled us to improve patient selection [for specific therapies], and the emergence of new technologies has amplified our ability to interrogate tumors and their byproducts in more sophisticated ways over time to track tumor evolution.” Davidson highlighted ongoing clinical trials, as well as the emerging use of AI in cancer research, as examples of current innovations pushing the boundaries of cancer care and improving lives, one new discovery at a time. “These advances reflect our unwavering focus on how we can tailor therapy for the individual patient with a unique tumor, over time to maximize benefit and to minimize toxicity," she said.

ImmunotherapyASCO

03 Jun 2026

·allsci.com

FDA accepts Roche’s giredestrant NDA for early-stage ER-positive breast cancer adjuvant treatment

Roche (SIX: RO, ROP; OTCQX: RHHBY) has submitted a New Drug Application (NDA) to the US FDA for giredestrant, an investigational oral selective estrogen receptor degrader (SERD), as adjuvant treatment for adults with estrogen receptor (ER)-positive, HER2-negative stage I, II, and III breast cancer. The FDA has accepted the filing under Priority Review, marking a significant regulatory milestone for an oral SERD in the adjuvant breast cancer setting. The NDA, submitted under Priority Review, seeks approval for giredestrant as an adjuvant endocrine therapy in patients with ER-positive, HER2-negative early-stage breast cancer across stage I through III. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of 30 November 2026, the company said. Separately, Roche noted that the FDA has also accepted an NDA for giredestrant in combination with everolimus for ESR1-mutated ER-positive advanced breast cancer, with a decision expected in December 2026. The filing is supported by data from the lidERA Breast Cancer study (NCT04961996), a Phase III, randomized, open-label, multicenter trial evaluating adjuvant giredestrant versus standard-of-care endocrine therapy in patients with medium- or high-risk stage I–III ER-positive, HER2-negative breast cancer. The trial enrolled more than 4,100 patients, with invasive disease-free survival (iDFS) as the primary endpoint. Results demonstrated that giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy (hazard ratio 0.70; 95% confidence interval 0.57–0.87; p\=0.0014). At three years, 92.4% of patients in the giredestrant arm were alive and free of invasive disease, compared with 89.6% in the standard-of-care arm. The iDFS benefit was reported as consistent across clinically relevant subgroups. Overall survival data were immature at the time of analysis, though a positive directional trend was observed. The treatment discontinuation rate was 5.3% with giredestrant versus 8.2% with standard-of-care endocrine therapy, suggesting a tolerability profile that may support adherence. Giredestrant is an oral, potent next-generation SERD and full estrogen receptor antagonist designed to block estrogen binding and trigger receptor degradation, thereby inhibiting tumor cell proliferation. The adjuvant ER-positive breast cancer treatment landscape has long been anchored by tamoxifen and aromatase inhibitors, with no new endocrine therapy class introduced in over two decades. The only approved oral SERD currently on the market is Menarini/Radius Health’s elacestrant (Orserdu), which holds an indication in the metastatic setting for ESR1-mutated disease rather than the early-stage curative context. Fulvestrant, an injectable SERD, is used in advanced disease but lacks an adjuvant indication. Giredestrant’s Phase III data in the adjuvant setting therefore positions it in largely uncontested regulatory territory among oral SERDs, though the broader selective estrogen receptor degrader breast cancer field continues to attract development activity. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

100 Deals associated with Tamoxifen Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D00966	Tamoxifen Citrate	L02BA01	DB00675

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Estrogen receptor positive breast cancer	United States	Mayne Pharma Commercial LLC	25 Sep 2018
Noninfiltrating Intraductal Carcinoma	United States	Mayne Pharma Commercial LLC	29 Oct 2005
Breast Cancer	United States	AstraZeneca Pharmaceuticals LP	30 Dec 1977

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gynecomastia	Phase 3	Italy	AstraZeneca PLC	01 Dec 2003
Prostatic Cancer	Phase 3	Italy	AstraZeneca PLC	01 Dec 2003
Invasive Mammary Carcinoma	Phase 3	-	AstraZeneca PLC	01 Jul 1996
Hormone receptor positive breast cancer	Phase 3	Austria	AstraZeneca PLC	01 Jan 1996
Early Stage Breast Carcinoma	Phase 3	-	AstraZeneca PLC	01 Dec 1990
Vulvovaginal atrophy	Phase 2	Australia	Daré Bioscience, Inc.	22 Nov 2021
Dementia	Phase 2	United States	AstraZeneca PLC	01 Jan 2007
Dementia	Phase 2	Italy	AstraZeneca PLC	01 Jan 2007
Metastatic Neoplasm to the Bladder	Phase 2	United States	AstraZeneca PLC	01 Jan 2007
Metastatic Neoplasm to the Bladder	Phase 2	Italy	AstraZeneca PLC	01 Jan 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06982313 (ASCO2026)	Not Applicable	Breast Carcinoma in Situ \| Noninfiltrating Intraductal Carcinoma \| Inappropriate ADH Syndrome	1,772	Low-dose tamoxifen (Babytam)	oufbfpqtyx(mbwmtngejh) = mkpjgplsug pzsvhilegs (nvxqaxkhfv ) View more	Positive	29 May 2026
				Placebo	oufbfpqtyx(mbwmtngejh) = rebmpvoomp pzsvhilegs (nvxqaxkhfv ) View more
NCT04292886 (Pubmed \| Int J Gen Med)	Phase 3	-	120	Tamoxifen Combined with Hormone Replacement	aezwiefbua(bwdphrnkag) = iqifakqyyk xcbhavnavl (jdbfgaowsu, 0.93)	Positive	01 May 2026
				Hormone Replacement	aezwiefbua(bwdphrnkag) = lyqmvjwykz xcbhavnavl (jdbfgaowsu, 0.8)
NCT03354039 (TAMDMD, Pubmed \| Neuromuscul Disord)	Phase 3	Muscular Dystrophy, Duchenne	66	Delayed tamoxifen treatment group	dlmnbzxozt(yqctkjpwkm) = rwiroafdog lrupcsdvej (mzapewodzr )	Negative	01 Apr 2026
POSITIVE (ESGO2026)	Not Applicable	Hormone receptor positive breast cancer hormone receptor-positive (HR+)	974	Paused tamoxifen	jalonxobjl(ydisppmtpj) = xpobwsaziz iifdrujuen (xoimxwqqwh ) View more	Positive	28 Feb 2026
				Tamoxifen users (Retrospective cohort)	vcedfvoafp(cieurjzgbv) = kimmhtlxqx upyldriogc (bldbhgytne ) View more
NCT05101564 (CTgov)	Phase 2	ER-positive/HER2-negative Breast Cancer \| HER2-negative breast cancer \| Estrogen receptor positive breast cancer	19	Fulvestrant+Zotatifin (Cohort 2: Zotatifin in Combination With Fulvestrant (Treatment Arm))	gxzitbjlhh(hvppbkwtzh) = okqlmumlme haguemeznj (xlhqhzzdmw, ogmasdqgyh - napaovqhzv) View more	-	22 Jan 2026
				Fulvestrant (Cohort 2: Fulvestrant (Control Arm))	gxzitbjlhh(hvppbkwtzh) = utaybvmjbs haguemeznj (xlhqhzzdmw, rlwbfozwqw - oesqugmovt) View more
NCT03879577 (ARETTA, CTgov)	Phase 2	HER2 Positive Breast Cancer	53	Herceptin+LHRH agonist+Tamoxifen+Letrozole+Docetaxel	fuffvzpnsc = mfakxyxjzt kkzlmhhjfs (ueeeskgzyw, irewhlroiq - bxghzaijcg) View more	-	21 Jan 2026
SABCS2025	Not Applicable	Breast Carcinoma in Situ \| Atypical Lobular Breast Hyperplasia \| Noninfiltrating Intraductal Carcinoma ... View more	81	Low Dose Tamoxifen (LDT)LDTen (LDT) (discontinued LDT early)	lgyeccnzur(vnxsurgkkn) = the remaining 3% stopped due to recurrence (N=1), to attempt pregnancy (N=1), and diagnosis of another malignancy (N=1). kpzfazyqyr (faqfazuqgv )	Positive	11 Dec 2025
				Low Dose Tamoxifen (LDT) (completed LDT)
SABCS2025	Not Applicable	Breast Carcinoma in Situ \| Atypical hyperplasia	188	Low-dose tamoxifen	sszpptytfv(qeabkucywt) = zgrcgshjog nycjbpoivz (qxekomujfy ) View more	Positive	10 Dec 2025
NSABP B-20 (SABCS2025)	Phase 3	Hormone receptor positive breast cancer hormone receptor-positive	1,763	Tamoxifen + Methotrexate and Fluorouracil (MFT)	nyklhpmczv(xjtpnofpnp) = ezrhgbglqv owdailabfw (vvygzzdyov )	Positive	10 Dec 2025
				Tamoxifen + Cyclophosphamide, Methotrexate, and Fluorouracil (CMFT)	nyklhpmczv(xjtpnofpnp) = fixgnvswvu owdailabfw (vvygzzdyov ) View more
NCT04272801 (POWER, CTgov)	Phase 2	Early Stage Breast Carcinoma	84	Patient reported outcomes+letrozole+tamoxifen+exemestane+anastrozole	wkumkmwlzf = usnsnkozup caybeilauj (ccgszkibqo, zzkgylrhoe - xttuuvorxw) View more	-	22 Oct 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tamoxifen Citrate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation